EUCTR2004-001937-40-IT进行中（未招募）不适用
Randomized, open phase II study of immunization with the recombinant MAGE-3 protein combined with adjuvant AS02B or AS15 in patients with unresectable and progressive metastatic cutaneous melanoma.
E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER0 个研究点目标入组 68 人开始时间: 2007年2月14日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 68
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Randomized, open phase II study of immunization with the recombinant MAGE-3 protein combined with adjuvant AS02B or AS15 in patients with unresectable and progressive metastatic cutaneous melanomanresectable and progressive metastatic cutaneous melanomaMedDRA version: 7.0Level: LLTClassification code 10027155EUCTR2004-001937-40-ESEuropean Organisation for Research and Treatment of Cancer
进行中（未招募）
1 期
A Study of Safety and Clinical Activity of Cancer Immunotherapy Plus Chemotherapy in Metastatic Melanoma PatientsPatients with unresectable and progressive metastatic cutaneous melanoma, whose tumor expresses MAGE-A3.MedDRA version: 16.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 100000004864EUCTR2008-001918-25-BEGlaxoSmithKline Biologicals40
进行中（未招募）
1 期
A Study of Safety and Clinical Activity of Cancer Immunotherapy Plus Chemotherapy in Metastatic Melanoma PatientsEUCTR2008-001918-25-FRGlaxoSmithKline Biologicals48
进行中（未招募）
不适用
An open Phase II study of immunization with the recMAGE-A3 + AS01B Antigen-Specific Cancer Immunotherapeutic in patients with MAGE-A3-positive unresectable and progressive metastatic cutaneous melanoma. - MAGE3-AS01B-MEL-001 (MET)MAGE-A3-positive unresectable and progressive metastatic cutaneous melanoma.EUCTR2007-005203-18-GRGlaxoSmithKline Biologicals34
进行中（未招募）
不适用
An open label, Phase II study of vaccination with Survivin peptides emulsified in Montanide ISA 51VG after IMP 321 injection in prostate carcinoma patients with biochemical failure (PROVAX study) - NDProstate cancer, biochemical failure after all potentially curative standard local therapies (radiotherapy, brachytherapy and surgery) or biochemical progression while patients have castrated levels of testosterone or after first-line anti hormonal therapyMedDRA version: 12.1Level: LLTClassification code 10001200Term: Adenocarcinoma of the prostate stage IEUCTR2009-017798-39-ITISTITUTO NAZIONALE PER LA CURA TUMORI